THROMBOCYTHEMIA MYELOFIBROSIS (PET-MF)
Clinical trials for THROMBOCYTHEMIA MYELOFIBROSIS (PET-MF) explained in plain language.
Never miss a new study
Get alerted when new THROMBOCYTHEMIA MYELOFIBROSIS (PET-MF) trials appear
Sign up with your email to follow new studies for THROMBOCYTHEMIA MYELOFIBROSIS (PET-MF), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Desperate patients get early access to promising drug
Disease control AVAILABLEThis program provides early access to the drug ruxolitinib for people with serious or life-threatening conditions like certain blood cancers, severe COVID-19, or graft-versus-host disease. It is for patients who have no other treatment options and cannot join a clinical trial. Th…
Matched conditions: THROMBOCYTHEMIA MYELOFIBROSIS (PET-MF)
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Massive new study aims to unlock secrets of rare blood cancers
Knowledge-focused Recruiting nowThis long-term observational study is enrolling 5,000 adults with myeloproliferative neoplasms (MPNs)—rare blood cancers like polycythemia vera and myelofibrosis. Researchers will collect health records, patient surveys, and insurance data over at least five years to track sympto…
Matched conditions: THROMBOCYTHEMIA MYELOFIBROSIS (PET-MF)
Sponsor: MPN Research Foundation • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:13 UTC